VANCOUVER – AbCellera (NASDAQ:ABCL) announced today that Peter Thiel, a prominent technology investor and entrepreneur, has decided to step down from the company's Board of Directors for personal reasons, with his resignation taking effect on March 7, 2024.
Thiel has been a part of AbCellera's board since November 2020 and has contributed to the company as the Chairman of the Nominating and Corporate Governance Committee. Upon his departure, the board will decrease in size from six to five directors, and Dr. Andrew Lo, already a board member, will take over Thiel's responsibilities in the committee.
The company's CEO, Carl Hansen, Ph.D., acknowledged Thiel's contributions to AbCellera, particularly noting his mentorship over the past three years. Hansen expressed gratitude for the guidance Thiel provided, which he regarded as a privilege.
Thiel's decision to resign was not due to any disagreements with the company regarding its operations, policies, or practices, as per the statement provided by AbCellera. This announcement comes as AbCellera continues its work in the biotech industry, aiming to expedite the development of antibody-based medicines through its integrated approach that combines technology, data science, and automation.
This press release contains forward-looking statements regarding AbCellera's future operations and product development, which are subject to risks and uncertainties and may not reflect future results or performance. The company has not indicated any changes to its business strategies, capital use, or future objectives in light of Thiel's resignation.
The information reported is based on a press release statement from AbCellera Biologics Inc.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.